上海交通大学学报（医学版）

上海交通大学学报（医学版） >

2025 , Vol. 45 >Issue 1: 107 - 112

DOI: https://doi.org/10.3969/j.issn.1674-8115.2025.01.013

综述

双相障碍神经炎症机制的研究进展

  • 王晓红 ,
  • 方贻儒
展开
  • 1.上海交通大学医学院附属精神卫生中心精神科，上海 200030
    2.上海交通大学医学院附属瑞金医院情感障碍中心，上海 200025
王晓红（1996—），女，硕士生；电子信箱：xhw314@126.com。
方贻儒，主任医师，博士；电子信箱：yirufang@aliyun.com。

收稿日期: 2024-06-06

  录用日期: 2024-11-25

  网络出版日期: 2025-01-28

基金资助

上海市精神卫生中心临床研究中心重点项目(CRC2021DX01)

收起

Research progress on the neuroinflammation mechanisms in bipolar disorder

  • WANG Xiaohong ,
  • FANG Yiru
Expand
  • 1.Department of Psychiatry, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China
    2.Department of Psychiatry & Affective Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
FANG Yiru, E-mail: yirufang@aliyun.com。

Received date: 2024-06-06

  Accepted date: 2024-11-25

  Online published: 2025-01-28

Supported by

Key Project of the Clinical Research Center, Shanghai Mental Health Center(CRC2021DX01)

Fold

摘要

双相障碍是一种慢性复发性精神疾病，其特征是情绪及状态的极端波动，临床表现为躁狂发作、抑郁发作和混合发作等反复或交替出现。双相障碍发病机制复杂且尚未明了，而神经炎症被认为是其发生发展的关键因素之一，深入研究不仅有助于理解病因，也可能为开发新的治疗靶点提供方向。该文综述了近年来关于双相障碍神经炎症方面的相关研究，探讨了外周和中枢炎症及其关联标志物的变化，探索了其致病的潜在机制，并简要叙述了心境稳定剂及新型治疗药物在抗炎作用方面的机制和潜力，以期指出未来可能的研究方向。

关键词： 双相障碍; 神经胶质细胞; 神经炎症; 生物标志物

本文引用格式

王晓红 , 方贻儒 . 双相障碍神经炎症机制的研究进展[J]. 上海交通大学学报（医学版）, 2025 , 45(1) : 107 -112 . DOI: 10.3969/j.issn.1674-8115.2025.01.013

Abstract

Bipolar disorder (BD) is a chronic, recurrent mental illness characterized by extreme fluctuations in mood and state, clinically manifested as recurrent or alternating manic, depressive, and mixed episodes. The pathogenesis is complex and remains unknown, with neuroinflammation considered as a key factor in its development. In-depth research not only helps to understand the etiology, but also provides direction for the development of new therapeutic targets. This paper reviews recent studies on neuroinflammation in BD, discusses changes in peripheral and central inflammation and associated biomarkers, explores the underlying mechanisms of pathogenesis, and briefly describes the mechanisms and potential of mood stabilizers and new therapeutic drugs in anti-inflammatory effect, aiming to suggest possible future research directions.

Key words： bipolar disorder; neuroglial cell; neuroinflammation; biomarker

参考文献

1 HARRISON P J, GEDDES J R, TUNBRIDGE E M. The emerging neurobiology of bipolar disorder[J]. Focus (Am Psychiatr Publ), 2019, 17(3): 284-293.
2 BOBO W V. The diagnosis and management of bipolar Ⅰ and Ⅱ disorders: clinical practice update[J]. Mayo Clin Proc, 2017, 92(10): 1532-1551.
3 GRANDE I, BERK M, BIRMAHER B, et al. Bipolar disorder[J]. Lancet, 2016, 387(10027): 1561-1572.
4 GIRIDHARAN V V, SAYANA P, PINJARI O F, et al. Postmortem evidence of brain inflammatory markers in bipolar disorder: a systematic review[J]. Mol Psychiatry, 2020, 25(1): 94-113.
5 BAUER M E, TEIXEIRA A L. Neuroinflammation in mood disorders: role of regulatory immune cells[J]. Neuroimmunomodulation, 2021, 28(3): 99-107.
6 SAYANA P, COLPO G D, SIM?ES L R, et al. A systematic review of evidence for the role of inflammatory biomarkers in bipolar patients[J]. J Psychiatr Res, 2017, 92: 160-182.
7 SOLMI M, SURESH SHARMA M, OSIMO E F, et al. Peripheral levels of C-reactive protein, tumor necrosis factor-α, interleukin-6, and interleukin-1β across the mood spectrum in bipolar disorder: a meta-analysis of mean differences and variability[J]. Brain Behav Immun, 2021, 97: 193-203.
8 DADOULI K, JANHO M B, HATZIEFTHIMIOU A, et al. Neutrophil-to-lymphocyte, monocyte-to-lymphocyte, platelet-to-lymphocyte ratio and systemic immune-inflammatory index in different states of bipolar disorder[J]. Brain Sci, 2022, 12(8): 1034.
9 FIEDOROWICZ J G, PROSSIN A R, JOHNSON C P, et al. Peripheral inflammation during abnormal mood states in bipolar I disorder[J]. J Affect Disord, 2015, 187: 172-178.
10 VEGA-Nú?EZ A, GóMEZ-SáNCHEZ-LAFUENTE C, MAYORAL-CLERIES F, et al. Clinical value of inflammatory and neurotrophic biomarkers in bipolar disorder: a systematic review and meta-analysis[J]. Biomedicines, 2022, 10(6): 1368.
11 ROSENBLAT J D, MCINTYRE R S. Bipolar disorder and immune dysfunction: epidemiological findings, proposed pathophysiology and clinical implications[J]. Brain Sci, 2017, 7(11): 144.
12 TONIN P T, VALVASSORI S S, LOPES-BORGES J, et al. Effects of ouabain on cytokine/chemokine levels in an animal model of mania[J]. J Neuroimmunol, 2014, 276(1/2): 236-239.
13 VALVASSORI S S, AGUIAR-GERALDO J M, POSSAMAI-DELLA T, et al. Depressive-like behavior accompanies neuroinflammation in an animal model of bipolar disorder symptoms induced by ouabain[J]. Pharmacol Biochem Behav, 2022, 219: 173434.
14 FILHO A J M C, CUNHA N L, DE ARAúJO RODRIGUES P, et al. Doxycycline reverses cognitive impairment, neuroinflammation and oxidative imbalance induced by D-amphetamine mania model in mice: a promising drug repurposing for bipolar disorder treatment?[J]. Eur Neuropsychopharmacol, 2021, 42: 57-74.
15 NASCIMENTO C, NUNES P V, SUEMOTO C K, et al. Differential levels of inflammatory and neuroendocrine markers in the hippocampus and anterior cingulate cortex of bipolar disorder subjects: a post-mortem study[J]. Brain Behav Immun, 2020, 90: 286-293.
16 NASCIMENTO C, NUNES P V, LEITE R E P, et al. The relationship of neuropsychiatric symptoms with inflammatory markers in the hippocampus and cingulate cortex of bipolar disorder subjects: a post-mortem study[J]. J Psychiatr Res, 2024, 173: 25-33.
17 S?DERLUND J, OLSSON S K, SAMUELSSON M, et al. Elevation of cerebrospinal fluid interleukin-1? in bipolar disorder[J]. J Psychiatry Neurosci, 2011, 36(2): 114-118.
18 ISGREN A, JAKOBSSON J, P?LSSON E, et al. Increased cerebrospinal fluid interleukin-8 in bipolar disorder patients associated with lithium and antipsychotic treatment[J]. Brain Behav Immun, 2015, 43: 198-204.
19 ISGREN A, SELLGREN C, EKMAN C J, et al. Markers of neuroinflammation and neuronal injury in bipolar disorder: relation to prospective clinical outcomes[J]. Brain Behav Immun, 2017, 65: 195-201.
20 PATEL J P, FREY B N. Disruption in the blood-brain barrier: the missing link between brain and body inflammation in bipolar disorder?[J]. Neural Plast, 2015, 2015: 708306.
21 KAMINTSKY L, CAIRNS K A, VEKSLER R, et al. Blood-brain barrier imaging as a potential biomarker for bipolar disorder progression[J]. Neuroimage Clin, 2020, 26: 102049.
22 STERTZ L, MAGALH?ES P V S, KAPCZINSKI F. Is bipolar disorder an inflammatory condition? The relevance of microglial activation[J]. Curr Opin Psychiatry, 2013, 26(1): 19-26.
23 BENNO HAARMAN B C M, DER LEK R F R V, DE GROOT J C, et al. Neuroinflammation in bipolar disorder - A [(11)C]-(R)-PK11195 positron emission tomography study[J]. Brain Behav Immun, 2014, 40: 219-225.
24 HAARMAN B C, BURGER H, DOORDUIN J, et al. Volume, metabolites and neuroinflammation of the hippocampus in bipolar disorder - A combined magnetic resonance imaging and positron emission tomography study[J]. Brain Behav Immun, 2016, 56: 21-33.
25 NAKAGAWA Y, CHIBA. Diversity and plasticity of microglial cells in psychiatric and neurological disorders[J]. Pharmacol Ther, 2015, 154: 21-35.
26 OHGIDANI M, KATO T A, HARAGUCHI Y, et al. Microglial CD206 gene has potential as a state marker of bipolar disorder[J]. Front Immunol, 2016, 7: 676.
27 COLOMBO E, FARINA C. Astrocytes: key regulators of neuroinflammation[J]. Trends Immunol, 2016, 37(9): 608-620.
28 VADODARIA K C, MENDES A P D, MEI A, et al. Altered neuronal support and inflammatory response in bipolar disorder patient-derived astrocytes[J]. Stem Cell Reports, 2021, 16(4): 825-835.
29 ZHANG P F, HUANG H M, GAO X L, et al. Involvement of kynurenine metabolism in bipolar disorder: an updated review[J]. Front Psychiatry, 2021, 12: 677039.
30 van den AMEELE S, van NUIJS A L, LAI F Y, et al. A mood state-specific interaction between kynurenine metabolism and inflammation is present in bipolar disorder[J]. Bipolar Disord, 2020, 22(1): 59-69.
31 HAROON E, MILLER A H. Inflammation effects on glutamate as a pathway to neuroprogression in mood disorders[J]. Mod Trends Pharmacopsychiatry, 2017, 31: 37-55.
32 LONG J Y, LI B, DING P, et al. Correlations between multimodal neuroimaging and peripheral inflammation in different subtypes and mood states of bipolar disorder: a systematic review[J]. Int J Bipolar Disord, 2024, 12(1): 5.
33 BENEDETTI F, POLETTI S, HOOGENBOEZEM T A, et al. Inflammatory cytokines influence measures of white matter integrity in Bipolar Disorder[J]. J Affect Disord, 2016, 202: 1-9.
34 TSENG H H, CHANG H H, WEI S Y, et al. Peripheral inflammation is associated with dysfunctional corticostriatal circuitry and executive dysfunction in bipolar disorder patients[J]. Brain Behav Immun, 2021, 91: 695-702.
35 MANSUR R B, DELGADO-PERAZA F, SUBRAMANIAPILLAI M, et al. Extracellular vesicle biomarkers reveal inhibition of neuroinflammation by infliximab in association with antidepressant response in adults with bipolar depression[J]. Cells, 2020, 9(4): 895.
36 SAKRAJDA K, SZCZEPANKIEWICZ A. Inflammation-related changes in mood disorders and the immunomodulatory role of lithium[J]. Int J Mol Sci, 2021, 22(4): 1532.
37 G?TTERT R, FIDZINSKI P, KRAUS L, et al. Lithium inhibits tryptophan catabolism via the inflammation-induced kynurenine pathway in human microglia[J]. Glia, 2022, 70(3): 558-571.
38 van den AMEELE S, van DIERMEN L, STAELS W, et al. The effect of mood-stabilizing drugs on cytokine levels in bipolar disorder: a systematic review[J]. J Affect Disord, 2016, 203: 364-373.
39 ROSENBLAT J D, KAKAR R, BERK M, et al. Anti-inflammatory agents in the treatment of bipolar depression: a systematic review and meta-analysis[J]. Bipolar Disord, 2016, 18(2): 89-101.
40 SAVITZ J B, TEAGUE T K, MISAKI M, et al. Treatment of bipolar depression with minocycline and/or aspirin: an adaptive, 2 × 2 double-blind, randomized, placebo-controlled, phase IIA clinical trial[J]. Transl Psychiatry, 2018, 8(1): 27.
Options
文章导航

/

〈 〉